- There is a great need for a reliable way to diagnose ovarian cancer, especially in the early stages.
- Analysis of markers in blood offers many advantages in terms of cost and ease of sampling.
- Researchers at Moffitt Cancer Center have identified a panel of 21 proteins from patient plasma that correlate with ovarian cancer.
FEATURES AND BENEFITS
- The 21 proteins are differentially expressed in plasma, affording easy sampling from the patient.
- The panel is based on a large sample size of 160 women, improving reliability of the results.
- Eight of the proteins are differentially expressed in early stage ovarian cancer, where there is a great need for a reliable test.
- The protein panel offers promise as a clinical test for diagnosis, screening and monitoring therapy in ovarian cancer.
STAGE OF DEVELOPMENT
An assay is being developed for clinical validation studies.
Patent application pending.
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent